ACUFREE is the 3rd-generation technological evolution of previous medical devices from the Tinnitech Group. The 2016-2023 period generated 5 development phases with evolving operating systems and related devices resulting in two biennial testing phases.
ACUFREE 3rd-generation: eight years of research & development
Il Dispositivo oggi contiene alti standard di elettronica, componentistica e specifiche tecniche.
Durante tutto questo percorso abbiamo negoziato al meglio per contenere i costi degli sviluppi software e hardware, in particolare in questi anni post-Covid di cambiamento e complessità della manifattura ed elettronica internazionale nei rapporti Europa-Asia (es. microchip e circuiti stampati).
Riteniamo doverose queste premesse per spiegare i costi e quindi il prezzo finale di ACUFREE.
Acquista Acufree
Value and reasons for choosing ACUFREE
ACUFREE is a new method of treating Tinnitus which – although not guaranteeing results or effectiveness for all – is able to demonstrate, through repeated levels of certified quantitative and qualitative data and results, its major favourable impact for 7 out of 10 patients.
Qualitative factors
– The 2022-24 Hospital Clinical Protocol delved into the condition of perceived discomfort of the 50 sufferers treated with 5 international methods of evaluation of Tinnitus: THI, TFI, VAS, SF-36 (quality of life) and Hearing Sensitivity.
All 5 measurements showed a trend and favourable data both in the short term (3 months) and in the long term (1 year). A quantitative performance that consolidates the possibilities of perceived efficacy for those who follow treatment with ACUFREE.
– The 2025 “Real-Life” Clinical Protocol, carried ut to exactly same standards and personnel as the hospital program, achieved even higher rate of clinical relief as measured by THI and on an even higher majority of patients (9-out-of-10 instead of 7-out-of-10).
